Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Болезнь Кронa

Список литературы

  1. Ивашкин В.Т., Шелыгин Ю.А., Абдулганиева Д.И. и соавт. Клинические рекомендации по диагностике и лечению болезни Крона у взрослых (проект). Колопроктология. 2020;19(2):8-38. https://doi.org/10.33878/2073-7556-2020-19-2-8-38.
  2. Azevedo V, et al. Biosimilars: considerations for clinical practice. Considerations Med 2017;1:13–18.
  3. Гущина Ю.Ш., Зырянов С.К., Орлихина И.А. Клинические и фармакоэкономические аспекты изменения анти-ФНО терапии по немедицинским причинам // Качественная клиническая практика. – 2017. – №2. – С. 35-48.
  4. Franke A. Genome-wide meta-analysis increases to 71 the number of confermed Crohn’s disease susceptibility loci – Nature genet., 2010, v.42, p.1118-1125. 
  5. Maloy K.J., Powrie F. Intestinal homeostasis and its breakdown in inflammatory bowel disease – Nature insight, 2011, v.474, No7351, p.298-306.
  6. Strober W., Fuss I., Mannon P. The fundamental basis of inflammatory bowel disease – J. Clin. Investigation, 2007, v.117 (3), p.514-521.
  7. Langholz E., Munkholm P., Krasilnikoff P.A. Inflammatory bowel disease with onset in childhood. Clinical features, morbidity and mortality in a regional cohort. – Scand.J. Gastroenterol., 1997, v.32, p.139-147.
  8. Корниенко, Е.А. Воспалительные заболевания кишечника у детей / Е.А. Корниенко // М.: Прима Принт. - 2019. - 228 с.: ил. - ISBN 978-5-60442241-1-3.
  9. Benchimol EI, Fortinsky KJ, Gozdyra P, Van den Heuvel M, Van Limbergen J, Griffiths AM. Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends. Inflamm Bowel Dis. 2011;17(1):423-39.
  10. Patrick F van Rheenen, Marina Aloi, Amit Assa et al. The Medical Management of Paediatric Crohn’s Disease: an ECCO-ESPGHAN Guideline Update, Journal of Crohn"s and Colitis, 2020;, jjaa161, https://doi.org/10.1093/ecco-jcc/jjaa161.
  11. Bernstein C., et al. WHO global guidelines on Inflammatory Bowel Disease - Guidelines for the Diagnosis and Management of IBD in 2010. Inflamm Bowel Dis. 2010 Jan; 16:112–124. doi:10.1002/ibd.21048.
  12. Van Limbergen J, Russell RK, Drummond HE, Aldhous MC, Round NK, Nimmo ER, et al. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology 2008; 135(4):1114-22.
  13. Vernier-Massouille G, Balde M, Salleron J, Turck D, Dupas JL, Mouterde O, et al. Natural history of pediatric Crohn"s disease: a population-based cohort study. Gastroenterology 2008; 135(4): 1106-13.
  14. Pigneur B, Seksik P, Viola S, Viala J, Beaugerie L, Girardet JP, et al. Natural history of Crohn"s disease: comparison between childhood- and adult-onset disease. Inflamm Bowel Dis 2010; 16(6):953-61.
  15. Horsthuis K., Bipat S., Bennink R.J., Stoker J. Inflammatory bowel disease diagnosed with US, MR, scintigraphy, and CT: metaanalysis of prospective studies. Radiology. - 2008;247(1):64-79.
  16. Чашкова Е.Ю., Владимирова А.А., Неустроев В.Г. и соавт. Воспалительные заболевания толстой кишки - аспекты диагностики. Бюллетень Восточно-Сибирского научного центра СО РАМН. - 2011. - № 4-2. - с.209-221.
  17. Levine A., Koletzko S., Turner D., et al.  ESPGHAN revised Porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents – J.Pediatric Gasroenterol Nutr., 2014, v.58 (6), p.795-806.
  18. Waugh N, Cummins E, Royle P, Kandala NB, Shyangdan D, Arasaradnam R, et al. Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation. Health Technol Assess 2013;17:xv–xix, 1–211.
  19. D?britz J, Gerner P, Enninger A, Cla?en M, Radke M. Inflammatory Bowel Disease in Childhood and Adolescence. Dtsch Arztebl Int. 2017 May 12;114(19):331-338, 
  20. Oliveira SB, Monteiro IM. Diagnosis and management of inflammatory bowel disease in children. BMJ. 2017 May 31;357:j2083
  21. Mack DR, Langton C, Markowitz J, LeLeiko N, Griffiths A, Bousvaros A, Evans J, Kugathasan S, Otley A, Pfefferkorn M, Rosh J, Mezoff A, Moyer S, Oliva-Hemker M, Rothbaum R, Wyllie R, delRosario JF, Keljo D, Lerer T, Hyams J, Pediatric Inflammatory Bowel Disease Collaborative Research Group Pediatrics. 2007;119(6):1113.).
  22. Matowicka-Karna J. Markers of inflammation, activation of blood platelets and coagulation disorders in inflammatory bowel diseases. Postepy Hig Med Dosw (Online). 2016 Apr 13;70:305-12.
  23. Dai Y, Zhang Q, Olofson AM, Jhala N, Liu X. Celiac Disease: Updates on Pathology and Differential Diagnosis. Adv Anat Pathol. 2019 Sep;26(5):292-312. doi: 10.1097/PAP.0000000000000242.
  24. Ghishan FK, Kiela PR. Vitamins and Minerals in Inflammatory Bowel Disease. Gastroenterol Clin North Am. 2017 Dec;46(4):797-808.
  25. Pfeferkorn MD, Marshalleck FE, Saeed SA, et al. NASPGHAN Clinical Report on the Evaluation and Treatment of Pediatric Patients With Internal Penetrating Crohn Disease: Intraabdominal Abscess With and Without Fistula. JPGN 2013; 57:394–400. doi: 10.1097/MPG.0b013e31829ef8.
  26. Chen H, Liu Y, Fu L, Lin X, Fan D, Li C. Clinical utility of double-balloon enteroscopy in children: A single-centre experience in South China. J Paediatr Child Health. 2019 Feb;55(2):188-193.
  27. UchidaK, Yoshiyama S, Inoue M, Koike Y, Yasuda H, Fujikawa H, Okita Y, Araki T, Tanaka K, Kusunoki M. Double balloon enteroscopy for pediatric inflammatory bowel disease. Pediatr Int. 2012 Dec;54(6):806-9.
  28. MaltzR, Podberesky DJ, Saeed SA Imaging modalities in pediatric inflammatory bowel disease. Curr Opin Pediatr. 2014;26(5):590-6.
  29. Sturm, Maaser C, Calabrese E, eta al. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects. J Crohns Colitis. 2019 Mar 26;13(3):273-284. doi: 10.1093/ecco-jcc/jjy114. PMID: 30137278.
  30. Oliva S, Thomson M, de Ridder L, Mart?n-de-Carpi J, Van Biervliet S, Braegger C, Dias JA, Kolacek S, Miele E, Buderus S, Bronsky J, Winter H, Navas-L?pez VM, Assa A, Chong SKF, Afzal NA, Smets F, Shaoul R, Hussey S, Turner D, Cucchiara S. Endoscopy in Pediatric Inflammatory Bowel Disease: A Position Paper on Behalf of the Porto IBD Group of the European Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 2018 Sep;67(3):414-430.
  31. Magline D. D., Sandrasegaran K., Chiorean M., Dewitt J. et al. Radiologic investigations complement and add diagnostic information to capsule endoscopy of small-bowel diseases Am. J. Roentgenol. 2007. Vol. 189. N 2. P. 306–312.
  32. Spada C., Riccioni M. E., Costamagna G. Patients with known small bowel stricture or with symptoms of small bowel obstructionsecondary to Crohn’s disease should not perform video capsule endoscopy without being previously tested for small bowel patency // Am. J. Gastroenterol. 2007. Vol. 102. N 7. P. 1542–1543.
  33. Kopylov U, et al. Diagnostic yield of capsule endoscopy versus magnetic resonance enterography and small bowel contrast ultrasound in the evaluation of small bowel Crohn’s disease: Systematic review and meta-analysis. Dig Liver Dis 2017;49:854–63.
  34. Podg?rka J., Pacho R., Albrecht P. MR enterography imaging of Crohn’s disease in pediatric patients. Pol J Radiol, 2014; 79: 79-87 doi:10.12659/PJR.889760.
  35. Hijaz NM, Attard TM, Colombo JM, Mardis NJ, Friesen CA. Comparison of the use of wireless capsule endoscopy with magnetic resonance enterography in children with inflammatory bowel disease. World J Gastroenterol 2019; 25(28): 3808-3822. DOI:10.3748/wjg.v25.i28.3808.
  36. J-Y Hang, H-K Yoon, W K Kim, Y A Cho, J S Lee, C H Yoon, Y J Lee, K M Kim. Transperineal ultrasonography for evaluation of the perianal fistula and abscess in pediatric Crohn disease: preliminary study. Ultrasonography 2014;33:184-190 doi:10.14366/usg.14009.
  37. de Zoten EF, Pasternak BA, Mattei P, et al. Diagnosis and Treatment of Perianal Crohn Disease: NASPGHAN Clinical Report and Consensus Statement. JPGN. 2013 Sep; 57:401–412. doi: 10.1097/MPG.0b013e3182a025ee.
  38. Kolara M., Pilkingtona M., Winthropa A., MacDonalda H., Justinichb C., Soboleskic D., Slyc L., Hurlbut D. Free intestinal perforation in children with Crohn"s disease. Journal of Pediatric Surgery Case Reports 32 (2018) 5–10. doi:10.1016/j.epsc.2018.01.002.
  39. Sakka D, Cheung MS. Management of primary and secondary osteoporosis in children. Ther Adv Musculoskelet Dis. 2020 Nov 2;12:1759720X20969262.
  40. Herzog D, Bishop N, Glorieux F, Seidman EG Interpretation of bone mineral density values in pediatric Crohn"s disease Inflamm Bowel Dis. 1998;4(4):261-7.
  41. Gokhale R, Favus MJ, Karrison T, Sutton MM, Rich B, Kirschner BS,. Bone mineral density assessment in children with inflammatory bowel disease. Gastroenterology. 1998;114(5):902-11.
  42. Maratva K, Hradsky O, Matyskova J, Copova I, Soucek O, Sumnik Z, Bronsky J. Musculoskeletal system in children and adolescents with inflammatory bowel disease: normal muscle force, decreased trabecular bone mineral density and low prevalence of vertebral fractures. Eur J Pediatr. 2017 Oct;176(10):1355-1363.
  43. Magro F, Langner C, Driessen A, Ensari A, Geboes K, Mantzaris GJ, Villanacci V, Becheanu G, Borralho Nunes P, Cathomas G, Fries W, Jouret-Mourin A, Mescoli C, de Petris G, Rubio CA, Shepherd NA, Vieth M, Eliakim R; European Society of Pathology (ESP); European Crohn"s and Colitis Organisation (ECCO). European consensus on the histopathology of inflammatory bowel disease. J Crohns Colitis. 2013 Nov;7(10):827-51. doi: 10.1016/j.crohns.2013.06.001. Epub 2013 Jul 17. PMID: 23870728
  44. Feakins RM; British Society of Gastroenterology. Inflammatory bowel disease biopsies: updated British Society of Gastroenterology reporting guidelines. J Clin Pathol. 2013 Dec;66(12):1005-26. doi: 10.1136/jclinpath-2013-201885. Epub 2013 Sep 2. PMID: 23999270.
  45. Birimberg-Schwartz L, Zucker DM, Akriv A, Cucchiara S, Cameron FL, Wilson DC, Lazowska I, Yianni L, Paul SP, Romano C, Kolacek S, Buderus S, P?rregaard A, Russell RK, Escher JC, Turner D; Pediatric IBD Porto group of ESPGHAN. Development and Validation of Diagnostic Criteria for IBD Subtypes Including IBD-unclassified in Children: a Multicentre Study From the Pediatric IBD Porto Group of ESPGHAN. J Crohns Colitis. 2017 Sep 1;11(9):1078-1084. doi: 10.1093/ecco-jcc/jjx053. PMID: 2843089.
  46. HH. Uhlig, F Charbit-Henrion, D. Kotlarz. Clinical Genomics for the diagnosis of monogenic forms of inflammatory bowel disease: A Position Paper from The Paediatric IBD Porto Group of ESPGHAN. Journal of Pediatric Gastroenterology and Nutrition, Publish Ahead of Print.2021.DOI : 10.1097/MPG.0000000000003017.
  47. Ruemmele FM, Veres G, Kolho KL, Griffiths A, Levine A, Escher JC, et al; European Crohn"s and Colitis Organisation; European Society of Pediatric Gastroenterology,Hepatology and Nutrition. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn"s disease. J Crohns Colitis. 2014 Oct;8(10):1179-207. DOI: 10.1016/j.crohns.2014.04.005.
  48. van Rhenen PF, Aloi M, Assa A, Bronsky J, Escher JC, Fagerberg UL, Gasparetto M, Gerasimidis K, Griffiths A, Henderson P, Koletzko S, Kolho KL, Levine A, van Limbergen J, Martin de Carpi FJ, Navas-L?pez VM, Oliva S, de Ridder L, Russell RK, Shouval D, Spinelli A, Turner D, Wilson D, Wine E, Ruemmele FM. The Medical Management of Paediatric Crohn"s Disease: an ECCO-ESPGHAN Guideline Update. J Crohns Colitis. 2020 Oct 7:jjaa161. doi: 10.1093/ecco-jcc/jjaa161. Epub ahead of print. PMID: 33026087.
  49. Miele E, Shamir R, Aloi M, Assa A, Braegger C, Bronsky J, et al. Nutrition in Pediatric Inflammatory Bowel Disease: A Position Paper on Behalf of the Porto Inflammatory Bowel Disease Group of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 2018 Apr;66(4):687-708. DOI: 10.1097/MPG.0000000000001896.
  50. Хавкин АИ, Сорвачёва ТН, Рославцева ЕА. Патогенетическое обоснование диетотерапии болезни Крона у детей. Экспериментальная и клиническая гастроэнтерология. 2021;186(2):94-105. DOI: 10.31146/1682-8658-ecg-186-2-94-105.
  51. Hartman C, Berkowitz D, Weiss B, Shaoul R, Levine A, Adiv OE, Shapira R, Fradkin A, Wilschanski M, Tamir A, Shamir R. (2008) Isr Med Assoc J. 10(7):503-7.  Nutritional supplementation with polymeric diet enriched with transforming growth fac tor-beta 2 for children with Crohn’s disease.
  52. Levine A, Wine E, Assa A, Sigall Boneh R, Shaoul R, Kori M, Cohen S, Peleg S, Shamaly H, On A, Millman P, Abramas L, Ziv-Baran T, Grant S, Abitbol G, Dunn KA, Bielawski JP, Van Limbergen J. Crohn"s Disease Exclusion Diet Plus Partial Enteral Nutrition Induces Sustained Remission in a Randomized Controlled Trial. Gastroenterology. 2019 Aug;157(2):440-450.e8. doi: 10.1053/j.gastro.2019.04.021. Epub 2019 Jun 4.
  53. Ford AC, Bernstein CN, Khan KJ, Abreu MT, Marshall JK, Talley NJ, et al. Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011;106(4):590-9 [quiz 600].
  54. Escher JC. Budesonide versus prednisolone for the treatment of active Crohn"s disease in children: a randomized, double-blind, controlled, multicentre trial. Eur J Gastroenterol Hepatol 2004;16(1):47-54.
  55. Levine A, Weizman Z, Broide E, Shamir R, Shaoul R, Pacht A, et al. A comparison of budesonide and prednisone for the treatment of active pediatric Crohn disease. J Pediatr Gastroenterol Nutr 2003;36(2):248-52.
  56. Markowitz J, Grancher K, Kohn N, Lesser M, Daum F. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn"s disease. Gastroenterology 2000; 119(4):895-902.
  57. Berni Canani R, Terrin G, Borrelli O, Romano MT, Manguso F, Coruzzo A, et al. Short- and long-term therapeutic efficacy of nutritional therapy and corticosteroids in paediatric Crohn"s disease. Dig Liver Dis 2006;38(6):381-7.
  58. TungJ, Loftus Jr EV, Freese DK, El-YoussefM, Zinsmeister AR, Melton III LJ, et al. A population-based study of the frequency of corticosteroid resistance and dependence in pediatric patients with Crohn"s disease and ulcerative colitis. Inflamm Bowel Dis 2006;12(12):1093-100.
  59. Byron MA, Jackson J, Ansell BM. Effect of different corticosteroid regimens on hypothalamic-pituitary-adrenal axis and growth in juvenile chronic arthritis. J R Soc Med 1983;76(6): 452-7.
  60. Modigliani R, Mary JY, Simon JF, Cortot A, Soule JC, Gendre JP, et al. Clinical, biological, and endoscopic picture of attacks of Crohn"s disease. Evolution on prednisolone Groupe d"Etude Therapeutique des Affections Inflammatoires Digestives. Gastroenterology 1990;98(4):811-8.
  61. Borrelli O, Cordischi L, Cirulli M, Paganelli M, Labalestra V, Uccini S, et al. Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn"s disease: a randomized controlled open-label trial. Clin Gastroenterol Hepatol 2006;4(6):744-53.
  62. Mantzaris GJ, Christidou A, Sfakianakis M, Roussos A, Koilakou S, Petraki K, et al. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn"s disease. Inflamm Bowel Dis 2009;15(3):375-82.
  63. Jakobsen C, Munkholm P, Paerregaard A, Wewer V. Steroid dependency and pediatric inflammatory bowel disease in the era of immunomodulators–a population-based study. Inflamm Bowel Dis 2011; 17(8):1731 -40.
  64. Levine A, Kori M, Dinari G, Broide E, Shaoul R, Yerushalmi B, et al. Comparison of two dosing methods for induction of response and remission with oral budesonide in active pediatric Crohn"s disease: a randomized placebo-controlled trial. Inflamm Bowel Dis 2009; 15(7):1055-61.
  65. Dilger K, AlbererM, Busch A, Enninger A, Behrens R, Koletzko S, et al. Pharmacokinetics and pharmacodynamic action of budesonide in children with Crohn"s disease. Aliment Pharmacol Ther 2006;23(3):387-96.
  66. Huscher D, Thiele K, Gromnica-Ihle E, HeinG, DemaryW, Dreher R, et al. Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis 2009;68(7):1119-24.
  67. Cohen SA, Aloi M, Arumugam R, Baker R, Bax K, Kierku? J, Koletzko S, Lionetti P, Persson T, Eklund S. Enteric-coated budesonide for the induction and maintenance of remission of Crohn"s disease in children. Curr Med Res Opin. 2017 Jul;33(7):1261-1268. doi: 10.1080/03007995.2017.1313213. Epub 2017 Apr 19. PMID: 28420280
  68. Greenley RN, Stephens KA, Nguyen EU, Kunz JH, Janas L, Goday P, Schurman JV. Vitamin and mineral supplement adherence in pediatric inflammatory bowel disease. J Pediatr Psychol. 2013 Sep;38(8):883-92. doi: 10.1093/jpepsy/jst037. Epub 2013 Jul 1. PMID: 23818680/
  69. Gawronska A, Banasiuk M, Lachowicz D, Pituch H, Albrecht P, Banaszkiewicz A. Metronidazole or Rifaximin for Treatment of Clostridium difficile in Pediatric Patients with Inflammatory Bowel Disease: A Randomized Clinical Trial. Inflamm Bowel Dis. 2017 Dec;23(12):2209-2214.
  70. Barabino A, Torrente F, Ventura A, Cucchiara S, Castro M, Barbera C. Azathioprine in paediatric inflammatory bowel disease: an Italian multicentre survey. Aliment Pharmacol Ther 2002;16(6):1125-30.
  71. Jaspers GJ, Verkade HJ, Escher JC, de Ridder L, Taminiau JA, Rings EH. Azathioprine maintains first remission in newly diagnosed pediatric Crohn"s disease. Inflamm Bowel Dis 2006;12(9):831-6.
  72. Ramadas AV, Gunesh S, Thomas GA, Williams GT, Hawthorne AB. Natural history of Crohn"s disease in a population-based cohort from Cardiff (1986-2003): a study of changes in medical treatment and surgical resection rates. Gut 2010;59(9):1200-6.
  73. Peyrin-Biroulet L, Oussalah A, Williet N, Pillot C, Bresler L, Bigard MA. Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn"s disease. Gut 2011;60(7):930-6.
  74. CosnesJ, BourrierA, Laharie D, Nahon S, BouhnikY, Carbonnel F, et al. Early administration of azathioprine vs conventional management of Crohn"s Disease: a randomized controlled trial. Gastroenterology 2013;145(4):758-65 [e2; quize14-5].
  75. Panes J, Lopez-Sanroman A, Bermejo F, Garcia-Sanchez V, Esteve M, Torres Y, et al. Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn"s disease. Gastroenterology 2013;145(4):766-74 [e1].
  76. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al. Infliximab, azathioprine, or combination therapy for Crohn"s disease. N Engl J Med 2010;362(15):1383-95.
  77. Fuentes D, Torrente F, Keady S, Thirrupathy K, Thomson MA, Walker-Smith JA, et al. High-dose azathioprine in children with inflammatory bowel disease. Aliment Pharmacol Ther 2003;17(7):913-21.
  78. Gearry RB, Barclay ML, Burt MJ, Collett JA, Chapman BA. Thiopurine drug adverse effects in a population of New Zealand patients with inflammatory bowel disease. Pharmacoepidemiol Drug Saf 2004; 13(8):563-7.
  79. Hindorf U, Lindqvist M, Hildebrand H, Fagerberg U, Almer S. Adverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel disease. Aliment Pharmacol Ther 2006;24(2):331-42.
  80. Kirschner BS. Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastro¬enterology 1998; 115(4):813-21.
  81. Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Price S, et al. Serious infection and mortality in patients with Crohn"s disease: more than 5 years of follow-up in the TREAT registry. Am J Gastroenterol 2012;107(9):1409-22.
  82. Baldassano R, Colletti RB, Cucchiara S, DubinskyM, Escher JC, Faubion WA, et al. 41 serious infections and associated risk factors in patients receiving infliximab and immunotherapies for children with inflammatory bowel disease: develop registry data. Gastroenterology 2013;144(5 Suppl 1):S-11.
  83. Ledder OD, Lemberg DA, Ooi CY, Day AS. Are thiopurines always contraindicated after thiopurine-induced pancreatitis in inflammatory bowel disease? J Pediatr Gastroenterol Nutr 2013;57(5):583-6.
  84. Dubinsky MC, Yangf H, Hassard§ PV, Seidmanll EG, Kam LY, Abreu MT, et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002; 122(4): 904-15.
  85. Ansari A, Hassan C, Duley J, Marinaki A, Shobowale-Bakre EM, Seed P, et al. Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease. Aliment Pharmacol Ther 2002;16(10):1743-50.
  86. Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005; 54(8):1121 -5.
  87. Camus M, Seksik P, Bourrier A, Nion-Larmurier I, Sokol H, Baumer P, et al. Long-term outcome of patients with Crohn"s disease who respond to azathioprine. Clin Gastroenterol Hepatol 2013; 11 (4):389-94.
  88. Ashworth LA, Billett A, Mitchell P, Nuti F, Siegel C, Bousvaros A. Lymphoma risk in children and young adults with inflam¬matory bowel disease: analysis of a large single-center cohort. Inflamm Bowel Dis 2012;18(5):838-43.
  89. Colletti RB, Cucchiara S, Dubinsky M, Escher JC, Faubion WA, Fell J, et al. 833 malignancies in children receiving infliximab and other inflammatory bowel disease therapies: an inflam¬matory bowel disease multicenter, prospective, long-term registry of pediatric patients (develop) registry data. Gastro¬enterology 2013;144(5, Supplement 1):S-147.
  90. Kotlyar DS, Osterman MT, Diamond RH, Porter D, Blonski WC, Wasik M, et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflamma¬tory bowel disease. Clin Gastroenterol Hepatol 2011;9(1): e1-e41.
  91. Peyrin-Biroulet L, Khosrotehrani K, Carrat F, Bouvier AM, Chevaux JB, Simon T, et al. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflam¬matory bowel disease. Gastroenterology 2011; 141 (5): 1621-8 [e1-5].
  92. Singh H, Nugent Z, Demers AA, Bernstein CN. Increased risk of nonmelanoma skin cancers among individuals with inflam¬matory bowel disease. Gastroenterology 2011; 141 (5): 1612-20.
  93. van Schaik FD, van Oijen MG, Smeets HM, van der Heijden GJ, Siersema PD, Oldenburg B. Thiopurines prevent advanced colorectal neoplasia in patients with inflammatory bowel disease. Gut 2012;61(2):235-40.
  94. Lennard L. Assay of 6-thioinosinic acid and 6-thioguanine nucleotides, active metabolites of 6-mercaptopurine, in human red blood cells. J Chromatogr. 1987 Dec 25;423:169-78
  95. Dervieux T, Boulieu R. Simultaneous determination of 6-thioguanine and methyl 6-mercaptopurine nucleotides of azathioprine in red blood cells by HPLC. Clin Chem. 1998 Mar;44(3):551-5.
  96. Turner D, Grossman AB, Rosh J, Kugathasan S, Gilman AR, Baldassano R, et al. Methotrexate following unsuccessful thiopurine therapy in pediatric Crohn"s disease. Am J Gastroenterol 2007;102(12):2804-12 [quiz 3, 13].
  97. Uhlen S, Belbouab R, Narebski K, Goulet O, Schmitz J, Cezard JP, et al. Efficacy of methotrexate in pediatric Crohn"s disease: a French multicenter study. Inflamm Bowel Dis 2006; 12(11): 1053-7.
  98. Boyle B, Mackner L, Ross C, Moses J, Kumar S, Crandall W. A single-center experience with methotrexate after thiopurine therapy in pediatric Crohn disease. J Pediatr Gastroenterol Nutr 2010;51(6):714-7.
  99. Mack DR, Young R, Kaufman SS, Ramey L, Vanderhoof JA. Methotrexate in patients with Crohn"s disease after 6-mercaptopurine. J Pediatr 1998;132(5):830-5.
  100. Ravikumara M, Hinsberger A, Spray CH. Role of methotrexate in the management of Crohn disease. J Pediatr Gastroenterol Nutr 2007;44(4):427-30.
  101. Weiss B, Lerner A, Shapiro R, Broide E, Levine A, Fradkin A, et al. Methotrexate treatment in pediatric Crohn disease patients intolerant or resistant to purine analogues. J Pediatr Gastroenterol Nutr 2009;48(5):526-30.
  102. Willot S, Noble A, Deslandres C. Methotrexate in the treatment of inflammatory bowel disease: an 8-year retrospective study in a Canadian pediatric IBD center. Inflamm Bowel Dis 2011;17(12):2521-6.
  103. Laharie D, Reffet A, Belleannee G, Chabrun E, Subtil C, Razaire S, et al. Mucosal healing with methotrexate in Crohn"s disease: a prospective comparative study with azathioprine and infliximab. Aliment Pharmacol Ther 2011;33(6):714-21.
  104. Hashkes PJ, Becker ML, Cabral DA, Laxer RM, Paller AS, Rabinovich CE, et al. Methotrexate: new uses for an old drug. J Pediatr 2014;164:231-6.
  105. Kempinska A, Benchimol EI, Mack A, Barkey J, Boland M, Mack DR. Short-course ondansetron for the prevention of methotrexate-induced nausea in children with Crohn disease. J Pediatr Gastroenterol Nutr 2011;53(4):389-93.
  106. Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn"s disease in children. Gastroenterology 2007;132(3):863-73 [quiz 1165-6].
  107. Kugathasan S, Werlin SL, Martinez A, Rivera MT, Heikenen JB, Binion DG. Prolonged duration of response to infliximab in early but not late pediatric Crohn"s disease. Am J Gastroenterol 2000;95(11): 3189-94.
  108. Hyams JS, Griffiths A, Markowitz J, Baldassano RN, Faubion Jr WA, Colletti RB, et al. Safety and efficacy of adalimumab for moderate to severe Crohn"s disease in children. Gastroenter¬ology 2012; 143(2):365-74 [e2].
  109. Rosh JR, Lerer T, Markowitz J, Goli SR, Mamula P, Noe JD, et al. Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn"s disease. Am J Gastroenterol 2009;104(12):3042-9.
  110. Crandall W, Hyams J, Kugathasan S, Griffiths A, Zrubek J, Olson A, et al. Infliximab therapy in children with concurrent perianal Crohn disease: observations from REACH. J Pediatr Gastroenterol Nutr 2009;49(2):183-90.
  111. Teitelbaum JE, Saeed S, Triantafyllopoulou M, Daum F. Infliximab in pediatric Crohn disease patients with enterovesicular fistulas. J Pediatr Gastroenterol Nutr 2007;44(2):279-82.
  112. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, et al. Infliximab for the treatment of fistulas in patients with Crohn"s disease. N Engl J Med 1999;340(18): 1398-405.
  113. Panaccione R, Loftus Jr EV, Binion D, McHugh K, Alam S, Chen N, et al. Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn"s disease: results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn"s DiseaSe (ACCESS) trial. Can J Gastroenterol 2011;25(8): 419-25.
  114. Dewint P, Hansen BE, Verhey E, Oldenburg B, Hommes DW, Pierik M, et al. Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn"s disease: a randomised, double-blind, placebo con-trolled trial (ADAFI). Gut 2014;63:292-9.
  115. Barrie A, Regueiro M. Biologic therapy in the management of extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel Dis 2007; 13 (11):1424-9.
  116. Kugathasan S, Miranda A, Nocton J, Drolet BA, Raasch C, Binion DG. Dermatologic manifestations of Crohn disease in children: response to infliximab. J Pediatr Gastroenterol Nutr 2003;37(2): 150-4.
  117. Escher JC, Stoof TJ, van Deventer SJ, van Furth AM. Successful treatment of metastatic Crohn disease with infliximab. J Pediatr Gastroenterol Nutr 2002;34(4):420-3.
  118. Krishnan S, Banquet A, Newman L, Katta U, Patil A, Dozor AJ. Lung lesions in children with Crohn"s disease presenting as nonresolving pneumonias and response to infliximab therapy. Pediatrics 2006;117(4):1440-3.
  119. Silbermintz A, Krishnan S, Banquet A, Markowitz J. Granulo¬matous pneumonitis, sclerosing cholangitis, and pancreatitis in a child with Crohn disease: response to infliximab. J Pediatr Gastroenterol Nutr 2006;42(3):324-6.
  120. Carpenter E, Jackson MA, Friesen CA, Scarbrough M, Roberts CC. Crohn"s-associated chronic recurrent multifocal osteomy¬elitis responsive to infliximab. J Pediatr 2004;144(4):541-4.
  121. Kierkus J, Dadalski M, Szymanska E, Oracz G, Wegner A, Gorczewska M, et al. The impact of infliximab induction therapy on mucosal healing and clinical remission in Polish pediatric patients with moderate-to-severe Crohn"s disease. Eur J Gastroenterol Hepatol 2012;24(5):495-500.
  122. Malik S, Ahmed SF, Wilson ML, Shah N, Loganathan S, Naik S, et al. The effects of anti-TNF-alpha treatment with adalimumab on growth in children with Crohn"s disease (CD). J Crohns Colitis 2012;6(3):337-44.
  123. Ryan BM, Russel MG, Schurgers L, Wichers M, Sijbrandij J, Stockbrugger RW, et al. Effect of antitumour necrosis factor-alpha therapy on bone turnover in patients with active Crohn"s disease: a prospective study. Aliment Pharmacol Ther 2004;20(8):851-7.
  124. Franchimont N, Putzeys V, Collette J, Vermeire S, Rutgeerts P, De Vos M, et al. Rapid improvement of bone metabolism after infliximab treatment in Crohn"s disease. Aliment Pharmacol Ther 2004; 20(6):607-14.
  125. Thayu M, Leonard MB, Hyams JS, Crandall WV, Kugathasan S, Otley AR, et al. Improvement in biomarkers of bone formation during infliximab therapy in pediatric Crohn"s disease: results of the REACH study. Clin Gastroenterol Hepatol 2008;6(12): 1378-84.
  126. Miheller P, Kiss LS, Lorinczy K, Lakatos PL. Anti-TNF trough levels and detection of antibodies to anti-TNF in inflammatory bowel disease: are they ready for everyday clinical use? Expert Opin Biol Ther 2012;12(2):179-92.
  127. Steenholdt C, Brynskov J, Thomsen OO, Munck LK, Fallingborg J, Christensen LA, et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn"s disease who lose response to anti-TNF treatment: a randomised, controlled trial. Gut 2014;63:919-27.
  128. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al. Infliximab, azathioprine, or combination therapy for Crohn"s disease. N Engl J Med 2010;362(15):1383-95.
  129. 1Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn"s disease: the ACCENT I randomised trial. Lancet 2002;3 59(9317):1541-9.
  130. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn"s disease: the CHARM trial. Gastroenterology 2007;132(1):52-65.
  131. Armuzzi A, Pugliese D, Danese S, Rizzo G, Felice C, Marzo M, et al. Infliximab in steroid-dependent ulcerative colitis: effectiveness and predictors of clinical and endoscopic remission. Inflamm Bowel Dis 2013;19(5):1065-72.
  132. Sprakes MB, Ford AC, Warren L, Greer D, Hamlin J. Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn"s disease: a large single centre experience. J Crohns Colitis 2012;6(2):143-53.
  133. Cucchiara S, Escher JC, Hildebrand H, Amil-Dias J, Stronati L, Ruemmele FM. Pediatric inflammatory bowel diseases and the risk of lymphoma: should we revise our treatment strategies? J Pediatr Gastroenterol Nutr 2009;48(3):257-67.
  134. Feagan BG, McDonald JW, Panaccione R, Enns RA, Bernstein CN, Ponich TP, et al. Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn"s disease. Gastroenterology 2014; 146:681 -8.
  135. Russell RK, Wilson ML, Loganathan S, Bourke B, Kiparissi F, Mahdi G, et al. A British Society of Paediatric Gastroenterol¬ogy, Hepatology and Nutrition survey of the effectiveness and safety of adalimumab in children with inflammatory bowel disease. Aliment Pharmacol Ther 2011;33(8):946-53.
  136. Kestens C, van Oijen MG, Mulder CL, van Bodegraven AA, Dijkstra G, de Jong D, et al. Adalimumab and infliximab are equally effective for Crohn"s disease in patients not previously treated with anti-tumor necrosis factor-alpha agents. Clin Gastroenterol Hepatol 2013; 11 (7):826-31.
  137. Baert F, Noman M, Vermeire S, Van Assche G, DH G, Carbonez A, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn"s disease. N Engl J Med 2003;348(7): 601-8.
  138. Miele E, Markowitz JE, Mamula P, Baldassano RN. Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab. J Pediatr Gastroenterol Nutr 2004;38(5):502-8.
  139. Candon S, Mosca A, Ruemmele F, Goulet O, Chatenoud L, Cezard JP. Clinical and biological consequences of immunization to infliximab in pediatric Crohn"s disease. Clin Immunol 2006; 118(1):11 -9.
  140. Wynands J, Belbouab R, Candon S, Talbotec C, Mougenot JF, Chatenoud L, et al. 12-month follow-up after successful infliximab therapy in pediatric crohn disease. J Pediatr Gastroenterol Nutr 2008;46(3):293-8.
  141. Lee LY, Sanderson JD, Irving PM. Anti-infliximab antibodies in inflammatory bowel disease: prevalence, infusion reactions, immunosuppression and response, a meta-analysis. Eur J Gastroenterol Hepatol 2012;24(9):1078-85.
  142. Jacobstein DA, Markowitz JE, Kirschner BS, Ferry G, Cohen SA, Gold BD, et al. Premedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium. Inflamm Bowel Dis 2005; 11 (5):442-6.
  143. Lahdenne P, Wikstrom AM, Aalto K, Kolho KL. Prevention of acute adverse events related to infliximab infusions in pediatric patients. Arthritis Care Res 2010;62(6):785-90.
  144. Kolho KL, Ruuska T, Savilahti E. Severe adverse reactions to infliximab therapy are common in young children with inflammatory bowel disease. Acta Paediatr 2007;96(1): 128-30 [Oslo, Norway : 1992].
  145. Hamalainen A, Lahdenne P, Wikstrom A, Aalto K, Kolho KL. Prevention of infusion reactions to infliximab in paediatric patients with oral acetylsalicylic acid. Clin Exp Rheumatol 2012;30(4):590-1.
  146. Fidder H, Schnitzler F, Ferrante M, Noman M, Katsanos K, Segaert S, et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 2009;58(4):501-8.
  147. de Bie CI, Escher JC, de Ridder L. Antitumor necrosis factor treatment for pediatric inflammatory bowel disease. Inflamm Bowel Dis 2012; 18(5):985-1002.
  148. Rahier JF, Ben-Horin S, Chowers Y, Conlon C, De Munter P, D"Haens G, et al. European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2009;3(2):47-91.
  149. Mackey AC, Green L, Leptak C, Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease: update. J Pediatr Gastroenterol Nutr 2009;48(3):386-8.
  150. Diak P, Siegel J, La Grenade L, Choi L, Lemery S, McMahon A. Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration. Arthritis Rheum 2010;62(8):2517-24.
  151. Hiremath G, Duffy L, Leibowitz I. Infliximab-induced psoriasis in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2011;52(2):230-2.
  152. Katz L, Gisbert JP, Manoogian B, Lin K, Steenholdt C, Mantzaris GJ, et al. Doubling the infliximab dose versus halving the infusion intervals in Crohn"s disease patients with loss of response. Inflamm Bowel Dis 2012; 18(11):2026-33.
  153. Vande Casteele N, Gils A, Singh S, Ohrmund L, Hauenstein S, Rutgeerts P, et al. Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol 2013; 108(6):962-71.
  154. Ben-Horin S, Waterman M, Kopylov U, Yavzori M, Picard O, Fudim E, et al. Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013; 11 (4):444-7.
  155. Karmiris K, Paintaud G, Noman M, Magdelaine-Beuzelin C, Ferrante M, Degenne D, et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn"s disease. Gastroenterology 2009; 137(5): 1628-40.
  156. Ardura MI, Toussi SS, Siegel JD, Lu Y, Bousvaros A, Crandall WNASPGHAN Clinical Report: Surveillance, Diagnosis, and Prevention of Infectious Diseases in Pediatric Patients With Inflammatory Bowel Disease Receiving Tumor Necrosis Factor-?Inhibitors.J Pediatr Gastroenterol Nutr. 2016 Jul;63(1):130-55.
  157. https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=ca33f239-4d15-4927-876f-223ca3671b01&t=
  158. MacDonald JK, Nguyen TM, Khanna R, Timmer A. Anti-IL-12/23p40 antibodies for induction of remission in Crohn’s disease. Cochrane Database Syst Rev 2016;11:CD 007572.
  159. Soler D, Chapman T, Yang LL, et al. The binding specificity and selective antagonism of vedolizumab, an anti-?4?7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther. 2009;330:864-875
  160. Singh N, Rabizadeh S, Jossen J, Pittman N, Check M, Hashemi G, Phan BL, Hyams JS, Dubinsky MC. Multi-Center Experience of Vedolizumab Effectiveness in Pediatric Inflammatory Bowel Disease. Inflamm Bowel Dis. 2016 Sep;22(9):2121-6. doi: 10.1097/MIB.0000000000000865. PMID: 27542130
  161. Ledder O, Assa A, Levine A, Escher JC, de Ridder L, Ruemmele F, Shah N, Shaoul R, Wolters VM, Rodrigues A, Uhlig HH, Posovszky C, Kolho KL, Jakobsen C, Cohen S, Shouval DS, de Meij T, Martin-de-Carpi J, Richmond L, Bronsky J, Friedman M, Turner D. Vedolizumab in Paediatric Inflammatory Bowel Disease: A Retrospective Multi-Centre Experience From the Paediatric IBD Porto Group of ESPGHAN. J Crohns Colitis. 2017 Oct 1;11(10):1230-1237. doi: 10.1093/ecco-jcc/jjx082. Erratum in: J Crohns Colitis. 2018 Apr 27;12(5):630. PMID: 28605483
  162. Luthra P, Peyrin-Biroulet L, Ford AC. Systematic review and meta- analysis: opportunistic infections and malignancies during treatment with anti-integrin antibodies in inflammatory bowel disease. Aliment Pharmacol Ther 2015;41:1227–36.
  163. de Ridder L, Assa A, Bronsky J, Romano C, Russell RK, Afzal NA, Hauer AC, Knafelz D, Lionetti P, Strisciuglio C, Veres G, Winter H, Wolters VM, Sladek M, Vulto AG, Dias JA; Paediatric IBD Porto group of ESPGHAN. Use of Biosimilars in Pediatric Inflammatory Bowel Disease: An Updated Position Statement of the Pediatric IBD Porto Group of ESPGHAN. J Pediatr Gastroenterol Nutr. 2019 Jan;68(1):144-153. doi: 10.1097/MPG.0000000000002141. PMID: 30169454.
  164. Материалы Всероссийской научно-практической конференции с международным участием «Российский колопроктологический форум» Колопроктология, том 18 №3s 2019, nch 11-12 https://doi.org/10.33878/2073-7556-2019-18-3-pril
  165. Franchimont D, Ferrante M, Louis E, De Vos M, Dewit O, Van Hootegem P, Moreels T, Liefferinckx C, Bossuyt P, Baert F, Rahier JF, Vermeire S. Belgian IBD research group (BIRD) position statement 2017 on the use of biosimilars in inflammatory bowel diseases (IBD). Acta Gastroenterol Belg. 2018 Jan-Mar;81(1):49-53. PMID: 29562378.
  166. Danese S, Fiorino G, Raine T, Ferrante M, Kemp K, Kierkus J, Lakatos PL, Mantzaris G, van der Woude J, Panes J, Peyrin-Biroulet L. ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease-An Update. J Crohns Colitis. 2017 Jan;11(1):26-34.
  167. Lourenc R, Azevedo S, Lopes AI. Surgery in Pediatric Crohn Disease: Case Series from a Single Tertiary Referral Center. GE Port J Gastroenterol. 2016; 23(4):191-196. doi:10.1016/j.jpge.2016.03.007.
  168. Gupta N, Bostrom AG, Kirschner BS, et al. Incidence of Stricturing and Penetrating Complications of Crohn’s Disease Diagnosed in Pediatric Patients. Inflamm Bowel Dis. 2010 Apr; 16(4):638–644. doi:10.1002/ibd.21099.
  169. Kim S. Surgery in Pediatric Crohn’s Disease: Indications, Timing and Post-Operative Management. Pediatr Gastroenterol Hepatol Nutr 2017 March 20(1):14-21. doi.org/10.5223/pghn.2017.20.1.14.
  170. Мазанкова Л.Н., Водилова О.В., Халиф И.Л. Осложнения болезни Крона у детей. Колопроктология. - 2004. - № 3 (9). - С. 30-35.
  171. Щербакова О.В. Практические рекомендации по хирургическому лечению осложненной болезни Крона у детей. Экспериментальная и клиническая гастроэнтерология. - 2015. - Т.1. - №113. - С.78-83.
  172. Aloi M, Viola F, D’Arcangelo G, et al. Disease course and efficacy of medical therapy in stricturing paediatric Crohn’s disease. Digestive and Liver Disease. 2013;45:464–468. doi:10.1016/j.dld.2013.01.020.
  173. Baillie CT, Smith JA. Surgical strategies in paediatric inflammatory bowel disease. World J Gastroenterol. 2015 May; 21(20):6101–6116. doi:10.3748/wjg.v21.i20.6101.
  174. Bemelman WA, Warusavitarne J, Sampietro GM, Serclova Z, Zmora O, Luglio G, de Buck van Overstraeten A, Burke JP, Buskens CJ,  Colombo F, Dias JA, Eliakim R, Elosua T, Gecim IE, Kolacek S, Kierkus J, Kolho KL, Lefevre JH, Millan M, Panis Y, Pinkney T, Russell RK, Shwaartz C, Vaizey C, Yassin N, D"Hoore A. ECCO-ESCP Consensus on Surgery for Crohn"s Disease. JCC, 2018, 12 (1): 1–16. doi:10.1093/ecco-jcc/jjx061.
  175. Abraham BP, Mehta S, El-Serag HB. Natural History of Pediatric-onset Inflammatory Bowel Disease. J Clin Gastroenterol. 2012 Aug; 46(7):581–589. doi:10.1097/MCG.0b013e318247c32f..
  176. Sentongo TA, Stettler N, Christian A, et al. Growth after intestinal resection for Crohn"s disease in children, adolescents, and young adults. Inflamm Bowel Dis 2000;6:265–9.
  177. Hojsak I, Kolacek S, Hansen LF, et al. Long-term outcomes after elective ileocecal resection in children with active localized Crohn"s disease - a multicenter European study. J Pediatr Surg. 2015 Oct; 50(10):1630-5. doi:10.1016/j.jpedsurg.2015.03.054. 
  178. Diefenbach KA, Breuer CK. Pediatric inflammatory bowel disease. World J Gastroenterol. 2006 May;12(20): 3204–3212. doi:10.3748/wjg.v12.i20.3204.
  179. Korzenik J.R. Massive lower gastrointestinal hemorrhage in Crohn’s disease. Curr. Treat Options Gastroenterol. - 2000;3:211-6.
  180. Werbin N., Haddad R., Greenberg R., et al. Free perforation in Crohn’s disease. Isr. Med. Assoc. J. - 2003;5:175-7.
  181. Joshi A, Bajwa R, Bhattacharjee N, et al. Bowel Perforation Associated With Infliximab Use in a Pediatrics Patient. WMJ. 2016 Apr; 115(2):90-92. 
  182. Traa MX, Orkin BA, Flores A, et al. Toxic colitis in a 10 year old girl with Crohn’s disease. J Ped Surg Case Reports. 2013; 1:284-287. doi.org/10.1016/j.epsc.2013.08.003.
  183. Papi C., Festa V., Fagnani C., et al. Evolution of clinical behaviour in Crohn’s disease: predictive factors of penetrating complications. Dig. Liver Dis. - 2005;37:247-53.
  184. Lightner AL, Vogler S, McMichael J, Jia X, Regueiro M, Qazi T, Steele SR. Dysplastic Progression to Adenocarcinoma is Equivalent in Ulcerative Colitis and Crohn"s Disease. J Crohns Colitis. 2021 Jan 13;15(1):24-34. doi: 10.1093/ecco-jcc/jjaa133. PMID: 32592468.
  185. Von Allmen D. Surgical management of Crohn"s disease in children. Curr Treat Options Gastroenterol. 2005 Oct; 8(5):405-10.
  186. Blackburn SC, Wiskin AE, Barnes C, et al. Surgery for children with Crohn’s disease: indications, complications and outcome. Arch Dis Child 2014; 99:420–426. doi:10.1136/archdischild-2013-305214.
  187. Boualit M, Salleron J, Turck D, et al. Long-term outcome after first intestinal resection in paediatric-onset Crohn"s disease: A population-based study. Inflamm Bowel Dis. 2013 Jan; 19(1):7-14. doi:10.1002/ibd.23004. 
  188. Levine A, Chanchlani N, Hussey S, Ziv-Baran T, Escher JC, Amil Dias J, Veres G, Koletzko S, Turner D, Kolho KL, Paerregaard A, Staiano A, Lionetti P, Nuti F, Sladek M, Shaoul R, Lazowska-Prezeorek I, Martin de Carpi J, Sigall Boneh R, Pfeffer Gik T, Cohen-Dolev N, Russell RK. Complicated Disease and Response to Initial Therapy Predicts Early Surgery in Paediatric Crohn"s Disease: Results From the Porto Group GROWTH Study. J Crohns Colitis. 2020 Jan 1;14(1):71-78. doi: 10.1093/ecco-jcc/jjz111.
  189. Dignass A, Van Assche G, Lindsay JO, Lemann M, Soderholm J, Colombel JF, et al. The second European evidence-based consensus on the diagnosis and management of Crohn"s disease: current management. J Crohns Colitis 2010;4(1):28-62.
  190. Amil-Dias J, Kolacek S, Turner D, P?rregaard A, Rintala R, Afzal NA, Karolewska-Bochenek K, Bronsky J, Chong S, Fell J, Hojsak I, Hugot JP, Koletzko S, Kumar D, Lazowska-Przeorek I, Lillehei C, Lionetti P, Martin-de-Carpi J, Pakarinen M, Ruemmele FM, Shaoul R, Spray C, Staiano A, Sugarman I, Wilson DC, Winter H, Kolho KL; IBD Working Group of ESPGHAN (IBD Porto Group). Surgical Management of Crohn Disease in Children: Guidelines From the Paediatric IBD Porto Group of ESPGHAN. J Pediatr Gastroenterol Nutr. 2017 May;64(5):818-835.
  191. Rieder F, Zimmermann EM, Remzi FH, et al. Crohn’s disease complicated by strictures: a systematic review. Gut. 2013; 62:1072–1084. doi:10.1136/gutjnl-2012-304353.
  192. Barkmeier DT, Dillman JR, Al-Hawary M, et al. MR enterography-histology comparison in resected pediatric small bowel Crohn disease strictures: can imaging predict fibrosis? Pediatr Radiol. 2016 Apr;46(4):498-507. doi:10.1007/s00247-015-3506-6. 
  193. Simillis C., Purkayastha S., Yamamoto T., et al. A meta-analysis comparing conventional end-to-end anastomosis vs. other anastomotic configurations after resection in Crohn"s disease. Dis. Colon Rectum. - 2007;50(10):1674-87.
  194. Diamond IR, Gerstle JT, Kim PC, Langer JC. Outcomes after laparoscopic surgery in children with inflammatory bowel disease. Surg Endosc. 2010 Nov;24(11):2796-802. doi: 10.1007/s00464-010-1050-x. Epub 2010 Apr 16. PMID: 20396907.
  195. Pini-Prato A, Faticato MG, Barabino A, et al. Minimally invasive surgery for paediatric inflammatory bowel disease: Personal experience and literature review. World J Gastroenterol. 2015 Oct; 21(40):11312–11320. doi:10.3748/wjg.v21.i40.11312.
  196. Kessler H, Mudter J, Hohenberger W. Recent results of laparoscopic surgery in inflammatory bowel disease. World J Gastroenterol. 2011 Mar 7;17(9):1116-25. doi: 10.3748/wjg.v17.i9.1116. PMID: 21448415; PMCID: PMC3063903.
  197. Воробьев Г.И., Болихов К.В., Варданян А.В. Место лапароскопической илеостомии в лечении болезни Крона толстой кишки (обзор литературы). Колопроктология. - 2009. - №3(29). - с. 52-58.
  198. Варданян А.В., Кашников В.Н., Болихов К.В., et al. Лапароскопическая илеостомия при болезни Крона. Журнал «Колопроктология». - 2011. - №3(37). - с. 20-23.
  199. Mahida JB, Asti L, Deans KJ, et al. Laparoscopic bowel resection for pediatric inflammatory bowel disease. J Surg Res. 2015 Nov; 199(1):130-6. doi:10.1016/j.jss.2015.04.009.
  200. Поддубный И. В., Алиева Э.И., Козлов М.Ю., Щербакова О.В. и соавт. Лапароскопические резекции кишечника у детей с болезнью Крона. Педиатрия. Журнал им.Г.Н.Сперанского. - 2015. - Т.94. - №6. - С.79-81.
  201. Bobanga ID, Bai S, Swanson MA, et al. Factors influencing disease recurrence after ileocolic resection in adult and pediatric onset Crohn’s disease. Am J Surg. 2014 Oct;208(4):591-6. doi:10.1016/j.amjsurg.2014.06.008. 
  202. Abdelaal K, Jaffray B. Colonic disease site and perioperative complications predict need for later intestinal interventions following intestinal resection in pediatric Crohn"s disease. J Pediatr Surg. 2016 Feb;51(2):272-6. doi:10.1016/j.jpedsurg.2015.10.078. 
  203. Page AE, Sashittal SG, Chatzizacharias NA, et al. The Role of Laparoscopic Surgery in the Management of Children and Adolescents With Inflammatory Bowel Disease. Medicine. 2015 May; 94(21):874-877. doi:10.1097/MD.0000000000000874.
  204. Diederen K, de Ridder L, van Rheenen P, et al. Complications and Disease Recurrence After Primary Ileocecal Resection in Pediatric Crohn"s Disease: A Multicenter Cohort Analysis. See comment in PubMed Commons belowInflamm Bowel Dis. 2017 Feb;23(2):272-282. doi:10.1097/MIB.0000000000000999.
  205. Bamford R, Hay A, Kumar D. Resection Leads to Less Recurrence Than Strictureplasty in a Paediatric Population with Obstructive Crohn"s Disease. Surg Res Pract. 2014; 2014:709045. doi:10.1155/2014/709045.
  206. Romeo E, Jasonni V, Caldaro T, et al. Strictureplasty and intestinal resection: different options in complicated pediatric-onset Crohn disease. J Pediatr Surg. 2012 May; 47(5):944-8. doi: 10.1016/j.jpedsurg.2012.01.054.
  207. Yamamoto T., Fazio V.W., Tekkis P.P. Safety and efficacy of strictureplasty for Crohn’s disease: a systematic review and meta-analysis. Dis. Colon Rectum. - 2007;50:1968-86.
  208. Reuken P. A., Kruis W., Maaser C., Teich N., Buning J., Preis J.C., Schmelz R., Bruns T., Fichtner-Feigl S., Stallmach A. Microbial Spectrum of Intra-Abdominal Abscesses in Perforating Crohn’s Disease: Results from a Prospective German Registry. Journal of Crohn"s and Colitis, 2018, 695–701. doi:10.1093/ecco-jcc/jjy017.
  209. Clancy C, Boland T, Deasy J, et al. A meta-analysis of percutaneous drainage versus surgery as the initial treatment of Crohn"s disease-related inta-abdominal abscess. J Crohns Colitis. 2016: 202-208. doi:10.1093/ecco-jcc/jjv198.
  210. Alkhouri RH, Bahia G, Smith AC, et al. Outcome of medical management of intraabdominal abscesses in children with Crohn"s disease. J Pediatr Surg. 2017 Mar;S0022-3468(17):30208-7. doi:10.1016/j.jpedsurg.2017.03.059. 
  211. Rypens F, Dubois J, Garel L, Deslandres C, Saint-Vil D. Percutaneous drainage of abdominal abscesses in pediatric Crohn"s disease. AJR Am J Roentgenol. 2007;188(2):579?585. doi:10.2214/AJR.06.0181.
  212. Dotson JL, Bashaw H, Nwomeh B, et al. Management of Intra-abdominal Abscesses in Children With Crohn’s Disease: A 12-year, Retrospective Single-center Review. Inflamm Bowel Dis. 2015 May; 21(5):1109–1114. doi:10.1097/MIB.0000000000000361
  213. Gecse K, Khanna R, Stoker J, Jenkins JT, Gabe S, Hahnloser D, D’Haens G. Fistulizing Crohn’s disease: Diagnosis and management. United European Gastroenterology Journal 2013; 1(3):206–213. doi:10.1177/2050640613487194.].
  214. Schecter WP, Hirshberg A, Chang DS, Harris HW, Napolitano LM, Wexner SD, et al. Enteric fistulas: principles of management. J Am Coll Surg. 2009;209(4):484-91.
  215. Tekkis P.P., Purkayastha S., Lanitis S., et al. A comparison of segmental vs. subtotal/total colectomy for colonic Crohn’s disease: a meta-analysis. Colorectal Dis. - 2006;8:82-90.
  216. Tichansky D., Cagir B., Yoo E., et al. Strictureplasty for Crohn’s disease: meta-analysis. Dis Colon Rectum. 2000;43:911-9.
  217. Reese G.E., Purkayastha S., Tilney H.S., et al. Strictureplasty vs. resection in small bowel Crohn’s disease: an evaluation of short-term outcomes and recurrence. Colorectal Dis. -2007;9:686-94.
  218. Maxwell EC., Dawany N, Baldassano RN, Mamula P, Mattei P, Albenberg L, Kelsen JR. Diverting Ileostomy for the Treatment of Severe, Refractory, Pediatric Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr. 2017 Sep;65(3):299-305. doi:10.1097/MPG.0000000000001498.
  219. Kariv Y, Remzi FH, Strong SA, et al. Ileal pouch rectal anastomosis: a viable alternative to permanent ileostomy in Crohn’s proctocolitis patients. J Am Coll Surg 2009;208:390–9. doi:10.1016/j.jamcollsurg.2008.10.037.
  220. Yamamoto T., Allan R.N., Keighley M.R. Effect of fecal diversion alone on perianal Crohn’s disease. World J. Surg. - 2000;24:1258-62.
  221. Singh Ranger G, Lamparelli MJ, Aldridge A, Chong SK, Mitton SG, Albanese A, et al. Surgery results in significant improvement in growth in children with Crohn"s disease refractory to medical therapy. Pediatr Surg Int. 2006;22(4):347-52.
  222. Melton G.B., Fazio V.W., Kiran R.P., et al. Long-term outcomes with ileal pouch-anal anastomosis and Crohn’s disease: pouch retention and implications of delayed diagnosis. Ann. Surg. - 2008;248:608-16.
  223. de Bie CI, Paerregaard A, Kolacek S, et al. Disease phenotype at diagnosis in pediatric Crohn"s disease: 5-year analyses of the EUROKIDS Registry. Inflammatory Bowel Diseases. 2013;19(2):378-85. 
  224. Bamford R, Hay A, Kumar D. Resection Leads to Less Recurrence Than Strictureplasty in a Paediatric Population with Obstructive Crohn"s Disease. Surg Res Pract. 2014; 2014:709045. doi:10.1155/2014/709045
  225. Di Nardo G, Oliva S, Passariello M, Pallotta N, Civitelli F, Frediani S, Gualdi G, Gandullia P, Mallardo S, Cucchiara S. Intralesional steroid injection after endoscopic balloon dilation in pediatric Crohn"s disease with stricture: a prospective, randomized, double-blind, controlled trial. Gastrointest Endosc. 2010 Dec;72(6):1201-8. doi:10.1016/j.gie.2010.08.003.
  226. Dietz D.W., Laureti S., Strong S.A., et al. Safety and longterm efficacy of strictureplasty in 314 patients with obstructing small bowel Crohn’s disease. J. Am. Coll. Surg. - 2001;192:330-7.
  227. Gionchetti P, Dignass A, Danese S, et al. 3rd European Evidence-Based Consensus on the Diagnosis and Management of Crohn"s Disease 2016: Part 2: Surgical Management and Special Situations. J Crohns Colitis. 2017; 11(2):135-149. doi:10.1093/ecco-jcc/jjw169.
  228. Aberra FN, Lewis JD, Hass D, et al. Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients. Gastroenterology. 2003;125(2):320-7.
  229. Lake J.P., Firoozmand E., Kang J.C., et al. Effect of high-dose steroids on anastomotic complications after proctocolectomy with ileal pouch-anal anastomosis. J. Gastrointest. Surg. – 2004; 8: 547-51.
  230. Kumar A, Auron M, Aneja A, et al. Inflammatory bowel disease: perioperative pharmacological considerations. Mayo Clin Proc. 2011; 86(8):748-757. doi:10.4065/mcp.2011.0074.
  231. Tay GS, Binion DG, Eastwood D, et al. Multivariate analysis suggests improved perioperative outcome in Crohn"s disease patients receiving immunomodulator therapy after segmental resection and/or strictureplasty. Surgery. 2003;134(4):565-72.
  232. Subramanian V., Pollok R.C., Kang J.Y., et al. Systematic review of postoperative complications in patients with inflammatory bowel disease treated with immunomodulators. Br. J. Surg. – 2006; 93: 793-9.
  233. Pugliese D., Armuzzi A., Rizzo G. et al. Effect of anti-TNF-alpha treatment on short-term post-operative complications in patients with inflammatory bowel disease. Gut. – 2010; 59 (Suppl III):A13. 
  234. Kopylov U, Ben-Horin S, Zmora O, et al. Anti-tumor necrosis factor and postoperative complications in Crohn"s disease: systematic review and meta-analysis. Inflammatory Bowel Diseases. 2012;18(12):2404-13.
  235. Billioud V, Ford AC, Tedesco ED. Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: A meta-analysis. J Crohns Colitis. 2013;7:853–867. doi:10.1016/j.crohns.2013.01.014.
  236. El-Hussuna A, Krag A, Olaison G, et al. The effect of anti-tumor necrosis factor alpha agents on postoperative anastomotic complications in Crohn"s disease: a systematic review. Diseases of the Colon & Rectum. 2013;56(12):1423-33.
  237. Yang ZP, Hong L, Wu Q, et al. Preoperative infliximab use and postoperative complications in Crohn"s disease: a systematic review and meta-analysis. International Journal Of Surgery. 2014;12(3):224-30.
  238. Adamina M, Gerasimidis K, Sigall-Boneh R, Zmora O, de Buck van Overstraeten A, Campmans-Kuijpers M, Ellul P, Katsanos K, Kotze PG, Noor N, Sch?fli-Thurnherr J, Vavricka S, Wall C, Wierdsma N, Yassin N, Lomer M. Perioperative Dietary Therapy in Inflammatory Bowel Disease. J Crohns Colitis. 2020 May 21;14(4):431-444. doi: 10.1093/ecco-jcc/jjz160. PMID: 31550347.
  239. Wagner IJ, Rombeau JL. Nutritional support of surgical patients with inflammatory bowel disease. Surg Clin North Am. 2011 Aug;91(4):787-803, viii. doi: 10.1016/j.suc.2011.04.013.
  240. Li Y, Zuo L, Zhu W, et al. Role of exclusive enteral nutrition in the preoperative optimization of patients with Crohn"s disease following immunosuppressive therapy. Medicine (Baltimore). 2015;94(5):e478. 
  241. Baldassano RN, Han PD, Jeshion WC, Berlin JA, Piccoli DA, Lautenbach E, Mick R, Lichtenstein GR. Pediatric Crohn"s disease: risk factors for postoperative recurrence. Am J Gastroenterol. 2001 Jul;96(7):2169-76. doi: 10.1111/j.1572-0241.2001.03876.x. PMID: 11467649
  242. Swoger JM, Regueiro M. Evaluation for postoperative recurrence of Crohn disease. Gastroenterol Clin North Am. 2012 Jun;41(2):303-14. doi: 10.1016/j.gtc.2012.01.011. PMID: 22500519
  243. Hansen LF, Jakobsen C, Paerregaard A, Qvist N, Wewer V. Surgery and postoperative recurrence in children with Crohn disease. J Pediatr Gastroenterol Nutr 2015;60:347-51. doi:10.1097/MPG.0000000000000616; Herfarth HH, Katz JA, Hanauer SB, et al.
  244. Bernell O, Lapidus A, Hellers G. Risk Factors for Surgery and Postoperative Recurrence in Crohn’s Disease. Ann Surg. 2000 Jan; 231(1):38-45. 
  245. Gasparetto M, Guariso G. Highlights in Inflammatory Bowel Disease: Epidemiology and Its Natural History in the Paediatric Age. Gastroenterol Res Pract. 2013; 829040:12. doi:10.1155/2013/829040.
  246. Hyams JS, Grand RJ, Colodny AH, Schuster SR, Eraklis A. Course and prognosis after colectomy and ileostomy for inflammatory bowel disease in childhood and adolescence. J Pediatr Surg. 1982 Aug;17(4):400-5. doi: 10.1016/s0022-3468(82)80498-3. PMID: 7120008
  247. Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn"s disease. Gastroenterology. 1990 Oct;99(4):956-63. doi: 10.1016/0016-5085(90)90613-6. PMID: 2394349
  248. Nguyen GC, Loftus EV Jr, Hirano I, Falck-Ytter Y, Singh S, Sultan S; AGA Institute Clinical Guidelines Committee. American Gastroenterological Association Institute Guideline on the Management of Crohn"s Disease After Surgical Resection. Gastroenterology. 2017 Jan;152(1):271-275. doi: 10.1053/j.gastro.2016.10.038. Epub 2016 Nov 10. PMID: 27840074
  249. Hukkinen M, Pakarinen MP, Merras-Salmio L, Koivusalo A, Rintala R, Kolho KL. Fecal calprotectin in the prediction of postoperative recur- rence of Crohn’s disease in children and adolescents. J Pediatr Surg 2016;51:1467–72.
  250. Yung DE, Har-Noy O, Tham YS, et al. Capsule endoscopy, magnetic resonance enterography, and small bowel ultrasound for evaluation of postoperative recurrence in Crohn’s Disease: systematic review and meta-analysis. Inflamm Bowel Dis 2017;24:93–100
  251. Tham YS, Yung DE, Fay S, et al. Fecal calprotectin for detec- tion of postoperative endoscopic recurrence in Crohn’s disease: systematic review and meta-analysis. Therap Adv Gastroenterol 2018;11:1756284818785571.
  252. Bakouny Z, Yared F, El Rassy E, et al. Comparative efficacy of anti-TNF therapies for the prevention of postoperative recurrence of Crohn’s dis- ease: a systematic review and network meta-analysis of prospective trials. J Clin Gastroenterol 2019;53:409–17
  253. Splawski JB, Pffefferkorn MD, Schaefer ME, Day AS, Soldes OS, Ponsky TA, Stein P, Kaplan JL, Saeed SA. NASPGHAN Clinical Report on Postoperative Recurrence in Pediatric Crohn Disease. J Pediatr Gastroenterol Nutr. 2017 Oct;65(4):475-486. doi: 10.1097/MPG.0000000000001606. PMID: 28937552
  254. Doherty G, Bennett G, Patil S, Cheifetz A, Moss AC. Interventions for prevention of post-operative recurrence of Crohn"s disease. Cochrane Database Syst Rev. 2009 Oct 7;(4):CD006873. doi: 10.1002/14651858.CD006873.pub2. PMID: 19821389
  255. Gjuladin-Hellon T, Gordon M, Iheozor-Ejiofor Z, Akobeng AK. Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn"s disease. Cochrane Database Syst Rev. 2019 Jun 20;6(6):CD008414. doi: 10.1002/14651858.CD008414.pub3. PMID: 31220875; PMCID: PMC6586553.
  256. American Society for Gastrointestinal Endoscopy Standards of Practice Committee, Shergill AK, Lightdale JR, Bruining DH, Acosta RD, Chandrasekhara V, Chathadi KV, Decker GA, Early DS, Evans JA, Fanelli RD, Fisher DA, Fonkalsrud L, Foley K, Hwang JH, Jue TL, Khashab MA, Muthusamy VR, Pasha SF, Saltzman JR, Sharaf R, Cash BD, DeWitt JM. The role of endoscopy in inflammatory bowel disease. Gastrointest Endosc. 2015 May;81(5):1101-21.e1-13. doi: 10.1016/j.gie.2014.10.030. Epub 2015 Mar 20. PMID: 25800660.
  257. Keljo DJ, Markowitz J, Langton C, et al. Course and Treatment of Perianal Disease in Children Newly Diagnosed with Crohn’s Disease. Inflamm Bowel Dis. 2009 Mar; 15(3):383-387. doi:10.1002/ibd.20767.
  258. Gecse KB, Bemelman W, Kamm MA, et al. A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn’s disease. Gut. 2014; 63:1381–1392. doi:10.1136/gutjnl-2013-306709.
  259. Водилова О.В., Мазанкова Л.Н., Халиф И.Л. Особенности течения болезни Крона в детском возрасте. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. - 2003. - Т.11. - №6. - С.69-73.
  260. Dupont-Lucas C, Dabadie A, Alberti C, Ruemmele FM; GETAID (Group d"Etude Th?rapeutique des Affections Inflammatoires du Tube Digestif) P?diatrique. Predictors of response to infliximab in paediatric perianal Crohn"s disease. Aliment Pharmacol Ther. 2014 Oct;40(8):917-29. doi: 10.1111/apt.12928. Epub 2014 Aug 22. PMID: 25146368.
  261. Forsdick VK, Tan Tanny SP, King SK. Medical and surgical management of pediatric perianal crohn"s disease: A systematic review. J Pediatr Surg. 2019 Dec;54(12):2554-2558. doi: 10.1016/j.jpedsurg.2019.08.036.
  262. Singer AAM, Gadepalli SK, Eder SJ, et al. Fistulizing Crohn’s Disease Presenting After Surgery on a Perianal Lesion. PEDIATRICS 2016 Mar; 137(3): e2 0152878. DOI: 10.1542/peds.2015-2878
  263. Bouguen G, Siproudhis L, Bretagne JF, Bigard MA, Peyrin-Biroulet L. Nonfistulizing perianal Crohn"s disease: clinical features, epidemiology, and treatment. Inflamm Bowel Dis. 2010 Aug;16(8):1431-42. doi:10.1002/ibd.21261.].
  264. Шелыгин Ю.А., Кашников В. Н., Болихов К. В. и соавт. Эффективность илеостомии при болезни Крона толстой кишки с перианальными поражениями. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. - 2011. - Т.21. - №6. - С.64-68.
  265. Щербакова О.В., Разумовский А.Ю., Шумилов П.В., Сытьков В.В. Хирургические подходы к лечению детей и подростков с перианальной болезнью Крона. Вестник хирургической гастроэнтерологии 2019. №4. С. 45-55.
  266. Short SS, Dubinsky MC, Rabizadeh S, et al. Distinct phenotypes of children with perianal perforating Crohn’s disease. J Pediatr Surg. 2013 Jun; 48(6):1301–1305. doi:10.1016/j.jpedsurg.2013.03.027.
  267. Al-Breiki S, Al-Faraidy N. A Crohn’s disease rectovaginal fistula in a nine year old girl masquerading as a case of sexual abuse, and literature review. Journal of the Saudi Society of Dermatology & Dermatologic Surgery. 2013;17:25–28. doi:10.1016/j.jssdds.2012.12.001.
  268. Шелыгин Ю.А., Кашников В. Н., Болихов К. В., Варданян А.В. Предикторы эффективности илеостомии при осложненных формах болезни Крона толстой кишки. Анналы хирургии. - 2012. - №3. - С.37-42.
  269. Akiba RT, Rodrigues FG, da Silva G. Management of Complex Perineal Fistula Disease. Clin Colon Rectal Surg. 2016 Jun;29(2):92-100. doi: 10.1055/s-0036-1580631. PMID: 27247533; PMCID: PMC4882183.
  270. Rosen MJ, Moulton DE, Koyama T, et al. Endoscopic Ultrasound to Guide the Combined Medical and Surgical Management of Pediatric Perianal Crohn"s Disease. Inflamm Bowel Dis. 2010 Mar; 16(3):461–468. doi:10.1002/ibd.21067.
  271. Seemann NM, Elkadri A, Walters TD, Langer JC. The role of surgery for children with perianal Crohn"s disease. J Pediatr Surg. 2015 Jan; 50(1):140-3. doi:10.1016/j.jpedsurg.2014.10.034.
  272. Assa A., Amitai M., Greer M.-L., Castro D. A, Kuint R.C., Mart?nez-Leon M., Herman-Sucharska I., Coppenrath E., Anupindi S., Towbin A., Moote D., Konen O., Pratt L., Griffiths A., Turner D. Perianal Pediatric Crohn Disease Is Associated With a Distinct Phenotype and Greater Inflammatory Burden. JPGN 2017;65: 293–298. doi:0.1097/MPG.0000000000001484.
  273. Dharmaraj R., Nugent M., Simpson P., Arca M., Gurram B., Werlin S. Outcomes after fecal diversion for colonic and perianal Crohn disease in children. J Pediatr Surg. 2017 Aug 24. pii: S0022-3468(17)30475-X. doi:10.1016/j.jpedsurg.2017.08.011
  274. Щербакова О.В., Разумовский А.Ю., Шумилов П.В., Ионов А.Л. Выбор оптимальной стратегии лечения детей с болезнью Крона и кроноподобными иммунодефицитами с перианальными поражениями. Вопросы детской диетологии. 2019. Т. 17. № 1. С. 7-16. DOI: 10.20953/1727-5784-2019-1-7-16.
  275. Forsdick VK, Tan Tanny SP, King SK. Medical and surgical management of pediatric perianal crohn"s disease: A systematic review. J Pediatr Surg. 2019 Dec;54(12):2554-2558. doi: 10.1016/j.jpedsurg.2019.08.036. Epub 2019 Oct 15. PMID: 31708205.
  276. Hain E., Maggiori L., Orville M., Tr?ton X., Bouhnik Y., Panis Y. Diverting Stoma for Refractory Ano-perineal Crohn’s Disease: Is It Really Useful in the Anti-TNF Era? A Multivariate Analysis in 74 Consecutive Patients. Journal of Crohn"s and Colitis, 2019, 572–577. doi:10.1093/ecco-jcc/jjy195.
  277. Galandiuk S, Kimberling J, Al-Mishlab TG, et al. Perianal Crohn Disease. Predictors of Need for Permanent Diversion. Ann Surg. 2005 May; 241(5):796–802. doi:10.1097/01.sla.0000161030.25860.c1.
  278. Gasparetto M, Guariso G, Visona L, et al. Clinical course and outcomes of diagnosing Inflammatory Bowel Disease in children 10 years and under: retrospective cohort study from two tertiary centres in the United Kingdom and in Italy. BMC Gastroenterology. 2016; 16:35. doi:10.1186/s12876-016-0455-y.
  279. Lawal TA, Frischer JS, Falcone RA, et al. The transanal approach with laparoscopy or laparotomy for the treatment of rectal strictures in Crohn"s disease. J Laparoendosc Adv Surg Tech A. 2010 Nov; 20(9):791-5. doi:10.1089/lap.2009.0470.
  280. Tozer PJ, Burling D, Gupta A, et al. Review article: medical, surgical and radiological management of perianal Crohn’s fistulas. Aliment Pharmacol Ther. 2011; 33:5–22.
  281. Головенко А.О., Халиф И.Л., Головенко О.В. Профилактика послеоперационных рецидивов болезни Крона (обзор литературы). Колопроктология. - 2012. - № 4 (42). - С.40-48.
  282. Engels M, Cross RK, Long MD. Exercise in patients with inflammatory bowel diseases: current perspectives. Clin Exp Gastroenterol. 2017 Dec 22;11:1-11. doi: 10.2147/CEG.S120816. PMID: 29317842; PMCID: PMC5743119.
  283. Vanhelst J, Vidal F, Turck D, Drumez E, Djeddi D, Devouge E, Spyckerelle C, Zandzou SG, Legrand C, Michaud L, B?ghin L, Gottrand F, Coopman S, Ley D. Physical activity is associated with improved bone health in children with inflammatory bowel disease. Clin Nutr. 2020 Jun;39(6):1793-1798]
  284. Lowe W, Kenwright D, Wyeth J, Blair N. Crohn disease: effect on children"s lifestyles. J Pediatr Gastroenterol Nutr. 2012 Mar;54(3):397-400. doi: 10.1097/MPG.0b013e318231cf17. PMID: 21857249.
  285. Farrell D, Artom M, Czuber-Dochan W, Jelsness-J?rgensen LP, Norton C, Savage E. Interventions for fatigue in inflammatory bowel disease. Cochrane Database Syst Rev. 2020 Apr 16;4(4):CD012005. doi: 10.1002/14651858.CD012005.pub2. PMID: 32297974; PMCID: PMC7161727.
  286. Martinelli M, Giugliano FP, Strisciuglio C, Urbonas V, Serban DE, Banaszkiewicz A, Assa A, Hojsak I, Lerchova T, Navas-L?pez VM, Romano C, Sladek M, Veres G, Aloi M, Kucinskiene R, Miele E. Vaccinations and Immunization Status in Pediatric Inflammatory Bowel Disease: A Multicenter Study From the Pediatric IBD Porto Group of the ESPGHAN. Inflamm Bowel Dis. 2020 Aug 20;26(9):1407-1414
  287. Dipasquale V, Romano C. Vaccination strategies in pediatric inflammatory bowel disease. Vaccine. 2017 Oct 27;35(45):6070-6075. doi: 10.1016/j.vaccine.2017.09.031. Epub 2017 Sep 28. PMID: 28967524
  288. Kammermeier J, Morris MA, Garrick V, et al. Management of Crohn’s disease. Arch Dis Child. 2016; 101:475–480. doi:10.1136/archdischild-2014-307217.
  289. Turner D, Griffiths AM, Walters TD, Seah T, Markowitz J, Pfefferkorn M, Keljo D, Waxman J, Otley A, LeLeiko NS, Mack D, Hyams J, Levine A. Mathematical weighting of the pediatric Crohn"s disease activity index (PCDAI) and comparison with its other short versions. Inflamm Bowel Dis. 2012 Jan;18(1):55-62
  290. Turner D, Levine A, Walters TD, Focht G, Otley A, L?pez VN, Koletzko S, Baldassano R, Mack D, Hyams J, Griffiths AM. Which PCDAI Version Best Reflects Intestinal Inflammation in Pediatric Crohn Disease? J Pediatr Gastroenterol Nutr. 2017 Feb;64(2):254-260
  291. De Cruz P, Kamm MA, Prideaux L, Allen PB, Desmond PV. Postoperative recurrent luminal Crohn"s disease: a systematic review. Inflamm Bowel Dis. 2012 Apr;18(4):758-77. doi: 10.1002/ibd.21825. Epub 2011 Aug 9. PMID: 21830279

Для продолжения работы требуется Registration
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Table of contents

Данный блок поддерживает скрол*